drugset / Trial / NCT03315494

Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy Volunteers

NCT03315494 ↗

Phase 1 Completed 24 enrolled Oscotec Inc. PPD Development, LP · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This double-blind, placebo-controlled, multiple ascending dose study is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of SKI-O-703 in healthy volunteers.

Timeline

Start
2016-09-22
Primary completion
2016-12-21
Completion
2016-12-21

Drugs

EvaluationDrugModalityDoseRoute
Subject SKI-O-703 Unknown 200 mg Oral
Subject SKI-O-703 Unknown 400 mg Oral

Indications